A meta-analysis on the safety of combination therapy with fenofibrate and statins

VernacularTitle:他汀类药物联用非诺贝特的安全性荟萃分析
Author: Qiang GENG ¹ ; Jing-Yi REN ; Su-Fang LI ; Hong CHEN
Author Information

1. 100044,北京大学人民医院心脏中心
Keywords: Antilipemic agents; Reproducility of results; Meta-analysis
From: Chinese Journal of Cardiology 2013;41(12):1063-1068
CountryChina
Language:Chinese
Abstract: Objective The aim of this study was to assess the safety of fenofibrate-statin combination therapy.Methods Medline,Cochrane Library,Web of Knowledge and CNKI were searched for 2184 randomized controlled trials.Finally,twenty-six studies with a total of 9494 participants were included in this analysis.Results Compared with statins group,the fenofibrate-statin group had significantly higher incidence of aminotransferase elevations (OR 1.67,95％ CI 1.22-2.30,P ＜ 0.05).The two groups had identical incidence of creatin kinase elevations (OR 0.86,95％ CI 0.62-1.20,P ＞ 0.05),muscleassociated adverse events (OR 0.98,95％ CI 0.88-1.09,P ＞ 0.05) and withdrawals due to hepatotoxicity or muscle toxicity.The safety of fenofibrate + standard-dose statin regimens were similar to those in fenofibrate-statin group.Conclusion Combined fenofibrate-statin treatment is generally safe and well tolerated,liver function should be monitored before and during and after therapy.